Access cutting-edge lung cancer treatment through this clinical trial at a research site in Sacramento. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Sacramento at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective
Sponsor: Nuvalent Inc.
Check if you qualify for this lung cancer clinical trial in Sacramento, CA
If you're searching for lung cancer treatment options in Sacramento, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Sacramento research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.